Nuformix hails "strategic opportunity" as proposes Biovara buy
(Alliance News) - Nuformix PLC on Wednesday said it has signed heads of terms for the proposed buy of Biovara Ltd.
Nuformix, the London-based pharmaceutical development company, said the proposed acquisition of Biovara represents an "important strategic opportunity".
The share-for-share deal will create a combined respiratory-focused pharmaceutical development business, bringing together Nuformix's idiopathic pulmonary fibrosis treatment NXP002 and Biovara's treatment for lung cancer-related cough LipAprep.
Nuformix said the transaction, payable in new Nuformix shares, is envisaged as a merger of equals. It said the combined valuation of the enlarged group is still to be agreed.
Nuformix Chair Tim Metcalfe said: "We believe the proposed acquisition of Biovara represents an important strategic opportunity for Nuformix and its shareholders, bringing together two complementary respiratory drug development programmes to create a more substantial and diversified clinical-stage respiratory business with the potential to unlock significant shareholder value."
Completion remains subject to due diligence, definitive transaction documentation and shareholder and regulatory approvals. The proposed transaction also includes cancellation of Nuformix's Main Market listing and admission of the enlarged group to AIM, with a long-stop date of April 30.
LipAprep has completed phase 1 single-dose clinical development and is being prepared for further clinical studies, including a phase 2 proof-of-concept trial Nuformix said.
Nuformix shares fell 9.1% to 0.096 pence on Wednesday morning in London.
By Niall Holden, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
Why Morningstar Thinks Anthropic Is Worth $1.7 Trillion
United States